IRIS
BATTAGLINI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.526
EU - Europa 5.459
AS - Asia 3.202
SA - Sud America 622
AF - Africa 201
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 7
Totale 17.025
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.429
GB - Regno Unito 1.494
CN - Cina 1.054
SG - Singapore 981
RU - Federazione Russa 945
IT - Italia 719
IE - Irlanda 652
BR - Brasile 509
UA - Ucraina 351
SE - Svezia 338
FR - Francia 316
VN - Vietnam 287
HK - Hong Kong 275
DE - Germania 249
KR - Corea 177
FI - Finlandia 145
ZA - Sudafrica 114
BD - Bangladesh 102
IN - India 81
ES - Italia 56
NL - Olanda 51
CA - Canada 45
TR - Turchia 45
AR - Argentina 42
MX - Messico 31
IQ - Iraq 27
BE - Belgio 24
NG - Nigeria 23
PK - Pakistan 23
PL - Polonia 19
EC - Ecuador 18
JP - Giappone 17
KE - Kenya 17
SA - Arabia Saudita 17
AT - Austria 15
IR - Iran 15
CH - Svizzera 14
PH - Filippine 14
MK - Macedonia 13
MA - Marocco 12
CL - Cile 11
CO - Colombia 11
UZ - Uzbekistan 11
VE - Venezuela 11
ID - Indonesia 10
CZ - Repubblica Ceca 9
EG - Egitto 9
PY - Paraguay 9
CI - Costa d'Avorio 8
AE - Emirati Arabi Uniti 7
DZ - Algeria 7
RO - Romania 7
BO - Bolivia 6
EU - Europa 6
GR - Grecia 6
JM - Giamaica 6
JO - Giordania 6
KZ - Kazakistan 6
MY - Malesia 6
NP - Nepal 6
RS - Serbia 6
AZ - Azerbaigian 5
IL - Israele 5
LT - Lituania 5
TN - Tunisia 5
AU - Australia 4
HU - Ungheria 4
AL - Albania 3
AM - Armenia 3
BN - Brunei Darussalam 3
DK - Danimarca 3
GE - Georgia 3
KG - Kirghizistan 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
PA - Panama 3
UY - Uruguay 3
BB - Barbados 2
BY - Bielorussia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
QA - Qatar 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BH - Bahrain 1
CU - Cuba 1
CY - Cipro 1
GH - Ghana 1
GT - Guatemala 1
HN - Honduras 1
Totale 17.017
Salva come PNG Salva come JPEG
Città #
Southend 1.322
Dallas 803
Fairfield 791
Dublin 646
Houston 576
Ashburn 519
Singapore 516
Woodbridge 413
Santa Clara 367
Chandler 357
Seattle 312
Wilmington 305
Jacksonville 284
Cambridge 276
San Jose 274
Beijing 263
Hong Kong 262
Moscow 259
Hefei 229
Menlo Park 184
Seoul 176
Ann Arbor 162
Princeton 128
The Dalles 127
Siena 125
Nanjing 110
Los Angeles 104
Johannesburg 103
Council Bluffs 99
Ho Chi Minh City 83
Milan 80
Hanoi 79
Lauterbourg 73
New York 72
Helsinki 67
Boardman 49
San Mateo 46
São Paulo 45
Buffalo 39
Dong Ket 37
Florence 36
Málaga 35
Nanchang 35
Columbus 33
Orem 32
Rome 31
San Diego 31
Shenyang 31
London 27
Pisa 25
Bengaluru 24
Abuja 23
Munich 23
Chicago 21
San Francisco 21
Brussels 20
Lancaster 20
Phoenix 20
Norwalk 19
Nuremberg 18
Frankfurt am Main 17
Redondo Beach 17
Chennai 16
Tianjin 16
Brasília 15
Naples 15
Rio de Janeiro 15
Warsaw 15
Dearborn 14
Hebei 14
Jiaxing 14
Kunming 14
Vicopisano 14
Changsha 13
Genoa 13
Jinan 13
Lappeenranta 13
Stockholm 13
Boston 12
Brooklyn 12
Düsseldorf 12
Montreal 12
Tokyo 12
Guarulhos 11
Izmir 11
Poplar 11
Shanghai 11
Turku 11
Atlanta 10
Belo Horizonte 10
Fremont 10
Mexico City 10
Amsterdam 9
Baghdad 9
Bari 9
Haiphong 9
Hangzhou 9
Livorno 9
Sarzana 9
Tashkent 9
Totale 11.775
Salva come PNG Salva come JPEG
Nome #
Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis 472
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes 309
Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis 299
SIENA-XL for improving the assessment of gray and white matter volume changes on brain MRI 285
Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis 281
The role of dentate nuclei in human oculomotor control: Insights from cerebrotendinous xanthomatosis 278
[(11)C]PBR28 or [(18)F]PBR111 detect white matter inflammatory heterogeneity in multiple sclerosis 277
A semiautomatic method for multiple sclerosis lesion segmentation on Dual-Echo MR imaging: Application in a multicenter context 270
Cortical damage in brains of patients with adult-form of myotonic dystrophy type 1 and no or minimal MRI abnormalities 270
Evidence of diffuse damage in frontal and occipital cortex in the brain of patients with post-traumatic stress disorder 260
Gray matter atrophy cannot be fully explained by white matter damage in patients with MS 259
Automated identification of brain new lesions in multiple sclerosis using subtraction images 253
Structural and metabolic damage in brains of patients with SPG11-related spastic paraplegia as detected by quantitative MRI 246
Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis 244
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. 244
Pronounced structural and functional damage in early adult pediatric-onset multiple sclerosis with no or minimal clinical disability 244
Brain atrophy assessment in multiple sclerosis: importance and limitations 242
Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis 241
Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome 241
Twelve-year monitoring of a patient with megalencephalic leukoencephalopathy with subcortical cysts 240
Relevance of brain lesion location to cognition in relapsing multiple sclerosis 240
Acute metabolic brain changes following traumatic brain injury and their relevance to clinical severity and outcome. 239
Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. 239
The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression 233
Cortical lesions in radiologically isolated syndrome. 231
Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis 230
Long-term assessment of no evidence of disease activity in relapsing-remitting MS 225
Prognostic biomarkers of IFNb therapy in multiple sclerosis patients 221
Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis 220
Early structural changes in individuals at risk of familial Alzheimer's disease. A volumetry and magnetization transfer MR imaging study 219
Deep gray matter volume loss drives disability worsening in multiple sclerosis 219
Progression of regional grey matter atrophy in multiple sclerosis 218
Magnetization Transfer Imaging Demonstrates a Distributed Pattern of Microstructural Changes of the Cerebral Cortex in Amyotrophic Lateral Sclerosis 204
Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. 204
Clinical and MRI measures to identify non-acute MOG-antibody disease in adults 200
Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. 200
Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization 197
Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI 195
Topiramate effects on plasma serotonin levels in children with epilepsy 195
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis 189
Diffuse structural and metabolic brain changes in Fabry disease 187
Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis 186
Brain MRI atrophy quantification in MS: From methods to clinical application 186
The dilemma of benign multiple sclerosis: Can we predict the risk of losing the “benign status”? A 12-year follow-up study 184
Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis 182
Evaluating and reducing the impact of white matter lesions on brain volume measurements 182
Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. 182
null 182
Lifespan normative data on rates of brain volume changes 179
T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis 176
Automated lesion segmentation with BIANCA: Impact of population-level features, classification algorithm and locally adaptive thresholding 176
Cortical functional reorganisation and its relationship with brain structural damage in patients with benign multiple sclerosis 176
Hippocampal atrophy and white matter lesions characteristics can predict evolution to dementia in patients with vascular mild cognitive impairment 173
Measuring Brain Atrophy in Multiple Sclerosis 173
Regional hippocampal atrophy reflects memory impairment in patients with early relapsing remitting multiple sclerosis 171
Modelling the distribution of cortical lesions in multiple sclerosis 168
Response to the letter “Progression of gray matter atrophy and its association with white matter lesions in relapsing–remitting multiple sclerosis” by Bendfeldt et al. 166
MRI correlates of disability in african-americans with multiple sclerosis 165
Diffuse metabolic changes in the brain of patients with familial amyloid polyneuropathy. A proton MRSI study. 163
Enhanced brain extraction improves the accuracy of brain atrophy estimation. 161
Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative 156
Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis 155
BIANCA (Brain Intensity AbNormality Classification Algorithm): a new tool for automated segmentation of white matter hyperintensities 154
Structural and Metabolic Brain Abnormalities in Preclinical Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarct and Leukoencephalopathy 153
Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis 151
Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis 151
Mapping the progressive treatment-related reduction of Active MRI lesions in multiple sclerosis 151
MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice 146
Magnetization Transfer MR Imaging Demonstrates Degeneration of the Subcortical and Cortical Gray Matter in Huntington Disease 144
Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis 144
Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course 139
Vitamin D levels in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) 138
MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies 131
Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis 127
Clinically relevant profiles of myelin content changes in patients with multiple sclerosis: a multimodal and multicompartment imaging study 126
Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets 124
Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a 124
Short-Term Combination of Glatiramer Acetate with IV Steroid Treatment Preceding Treatment with GA Alone Is Associated with early Suppression of MRI-disease activity in Patients with Relapsing Remitting Multiple Sclerosis 123
BIANCA-MS: An optimized tool for automated multiple sclerosis lesion segmentation 117
Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis 111
null 108
The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis 104
Evaluation of cervical spinal cord atrophy using a modified SIENA approach 103
Dynamic imaging of individual remyelination profiles in multiple sclerosis 101
Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis 98
Hippocampal atrophy in vascular MCI as biomarker of subclinical memory impairment 92
Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis 90
Quantification of [11C]PIB PET for imaging myelin in the human brain: A test-retest reproducibility study in high-resolution research tomography 88
Individual mapping of innate immune cell activation is a candidate marker of patient-specific trajectories of worsening disability in multiple sclerosis 79
Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes 79
Guiding differentiation of non-acute MOGAD from AQP4-NMOSD and RRMS using clinical and MRI measures 71
Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis 71
Neurophysiological, imaging and neurobiological markers of central fatigue in multiple sclerosis 27
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a 26
Linking movement-related beta oscillations to cortical excitability, structural damage, and fatigue in multiple sclerosis 21
Clinically Relevant Patterns of Co‐Fluctuating Structure and Function in Multiple Sclerosis 7
Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody–Associated Disease 7
Totale 17.228
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.544
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.544
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021128 0 0 0 0 0 0 0 0 0 0 0 128
2021/20221.103 82 128 89 93 54 45 71 35 62 95 149 200
2022/20231.394 80 100 158 181 146 233 42 164 157 54 45 34
2023/2024914 48 30 65 34 24 235 357 29 4 13 7 68
2024/20252.595 82 117 183 116 343 148 126 201 221 145 246 667
2025/20265.419 487 796 682 598 837 196 631 189 208 351 253 191
Totale 17.228